Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation

BACKGROUND: Exenatide (EXT), the first glucagon-like peptide-1 receptor agonist, has been approved as an adjunctive therapy for patients with type 2 diabetes. Due to EXT’s short half-life, EXT must be administrated by continuous subcutaneous (s.c.) injection twice daily. In previous studies, many st...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cuiwei, Zheng, Hongyue, Xu, Junjun, Shi, Xiaowei, Li, Fanzhu, Wang, Xuanshen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583966/
https://www.ncbi.nlm.nih.gov/pubmed/28870261
http://dx.doi.org/10.1186/s40199-017-0186-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583966/
https://www.ncbi.nlm.nih.gov/pubmed/28870261
http://dx.doi.org/10.1186/s40199-017-0186-9

Ejemplares similares